Oral GLP-1 Drug Orforglipron Cuts Blood Sugar and Weight in Type 2 Diabetes Trial
The ACHIEVE-5 trial shows orforglipron added to basal insulin significantly lowered HbA1c and reduced body weight without raising hypoglycemia risk.
Summary
A major international trial called ACHIEVE-5 found that orforglipron, a once-daily oral GLP-1 drug, meaningfully improved blood sugar control in adults with type 2 diabetes who weren't responding adequately to basal insulin alone. Patients saw HbA1c drop by up to 1.88 percentage points compared to 0.79 with placebo. Crucially, participants also lost 2.6% to 5.4% of body weight — even as their insulin doses increased by 30–33%, a combination that typically causes weight gain. No increase in dangerous low blood sugar episodes was observed. Gastrointestinal side effects like nausea were the main downside, with up to 9.6% discontinuing the highest dose. The results were presented at the ADA annual meeting and published simultaneously in JAMA.
Detailed Summary
Type 2 diabetes affects hundreds of millions globally, and many patients struggle to maintain healthy blood sugar levels even on insulin therapy. A new trial offers a promising oral solution that addresses both glucose control and weight — two of the most critical factors in long-term metabolic health and longevity.
The ACHIEVE-5 trial enrolled adults with type 2 diabetes who had inadequate glycemic control despite already using basal insulin (glargine). Participants were randomized to receive once-daily orforglipron at 3, 12, or 36 mg, or placebo, for 40 weeks. HbA1c reductions ranged from 1.58% to 1.88% across doses versus just 0.79% with placebo — a statistically significant and clinically meaningful difference across all doses tested.
Perhaps the most striking finding was weight loss. Orforglipron users lost 2.6% to 5.4% of body weight from baseline, while placebo patients gained an average of 0.2%. This occurred even as insulin doses climbed 30–33% in the orforglipron groups — circumstances that normally drive weight gain due to increased lipid storage and reduced fat breakdown. Editorialists called this combination clinically important, as weight gain is a major barrier to intensifying insulin therapy.
No increase in hypoglycemia risk was detected, which is a significant safety advantage when combining a glucose-lowering agent with insulin. However, gastrointestinal side effects were notable: treatment discontinuation due to nausea and vomiting reached 9.6% at the highest dose versus 3.6% with placebo — a real-world consideration for tolerability.
Orforglipron is an oral, nonpeptide GLP-1 receptor agonist recently FDA-approved for obesity. Unlike injectable GLP-1 drugs, its pill format may improve adherence. With cardiovascular safety data also emerging from ACHIEVE-4, orforglipron is building a strong evidence profile across multiple cardiometabolic conditions — making it a drug class worth watching for anyone focused on metabolic health and longevity.
Key Findings
- Orforglipron reduced HbA1c by up to 1.88% versus 0.79% with placebo in insulin-treated type 2 diabetes patients.
- Patients lost 2.6–5.4% body weight on orforglipron despite simultaneously increasing insulin doses by 30–33%.
- No increased hypoglycemia risk was observed when adding orforglipron to basal insulin therapy.
- Up to 9.6% of patients on the highest dose discontinued due to nausea and vomiting side effects.
- ACHIEVE-4 data also supports cardiovascular safety of orforglipron versus insulin glargine in high-risk patients.
Methodology
This is a news report from MedPage Today covering the ACHIEVE-5 randomized controlled trial, presented at the ADA 2026 annual meeting and simultaneously published in JAMA, a high-credibility peer-reviewed journal. The trial is international in scope and includes placebo-controlled comparisons across three active doses, providing robust evidence. Source credibility is high given dual ADA presentation and JAMA publication.
Study Limitations
The article is a meeting coverage summary and may not capture all trial design details, patient demographics, or full safety data available in the JAMA publication. The 40-week study duration limits conclusions about long-term outcomes and sustained weight loss. Generalizability may vary depending on baseline insulin regimens and comorbidities not detailed in this report.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.